Research on the Clinical Value of Cranial CT and CTA for Cerebral Hemorrhage Patients
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Intracerebral Hemorrhage (ICH). Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Research on the Clinical Value of Cranial CT and CTA in Patients With Cerebral Hemorrhage
Overview
The objective of this observational study is to investigate the predictive value of various imaging signs in patients with intracerebral hemorrhage, thereby providing a reference for clinical diagnosis and treatment. The primary aim is to evaluate the association between specific imaging signs and both hematoma expansion and poor outcomes in these patients.
Primary outcome measures
- Randomized 180-day mRS score of 0-3 (%) [Time frame: From the end of the six-month period after discharge.]
Eligibility criteria
Inclusion criteria
(1) Patients who were confirmed to have cerebral hemorrhage through head CT imaging examination upon admission; (2) Those who completed head CT and CTA within 8 hours of onset and had a follow-up CT within 24 hours of admission; (3) With complete clinical data.
Exclusion criteria
(1) Patients who cannot complete CT and CTA within the prescribed time; (2) Patients with secondary cerebral hemorrhage due to cerebral vascular malformations, brain tumors, brain trauma, cerebral aneurysms, etc.; (3) Patients who have been taking oral anticoagulants for a long time or have blood system diseases; (4) Primary intraventricular hemorrhage.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07100132 · GE2023JZ-01